M-CERSI Event

The Evolution of Biopharmaceutics: Risk Assessment and Clinical Relevance

Innovation in oral drug development is happening fast, and this two‑day workshop hosted by the University of Maryland CERSI and the FDA is your chance to be part of the conversation. This edition, it is focussed on the transformative approach towards the role of dissolution testing in regulatory decision making and explore how dissolution testing is moving beyond traditional quality control toward predictive, patient-focused science.

Our TIM PK expert, Connor, wil join the workshop and is ready to discuss how advanced GI simulation can support your projects! Also you don’t want to miss the talk by and don’t miss the exciting talk by Robert Schwabe, PhD from Boehringer Ingelheim Pharmaceuticals Inc. “From Established to Essential: How TIM Systems are Routinely Replacing In Vivo Assessments in Industry to Manage Biopharmaceutical Risk, and Accelerate Development”.